2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Cure Parkinson’s approves funding for new iron removing drug
Cure Parkinson’s continues to champion iron chelation for Parkinson’s. Trustees have now awarded a grant to develop the next generation of iron reducing drugs.
Gut feeling about bile acids
Researchers have reported that the ability of gut bacteria to break down fat is disrupted in people with Parkinson’s, resulting in issues with the production of bile acid.
Positioning prostate drugs for Parkinson’s
Researchers have published evidence that a class of drugs commonly used for the treatment of prostate enlargement may have beneficial properties for Parkinson’s.
Post-hoc analysis of steady-PD3 trial results
Recent post-hoc analysis of the Steady-PD3 trial data has highlighted some interesting effects.
‘AskBio’ acquires BNB and GDNF gene therapy trials
BNB and AskBio have joined forces to expand a gene therapy programme for Parkinson’s